ReviewFrontiers of medicine2013
Advances in immunopathogenesis of adult immune thrombocytopenia.
Review in Frontiers of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation.Annals of hematology · 2018Trial
- Correlation Between Fecal Microbiota and Corticosteroid Responsiveness in Primary Immune Thrombocytopenia: an Exploratory Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Effect of Different Induction Immunosuppression on the Incidence of Infectious Complications after Kidney Transplantation-Single Center Study.Journal of clinical medicine · 2024Article
- Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP.Blood advances · 2023Review
- Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency.Medicina (Kaunas, Lithuania) · 2021Article
- A Retrospective Analysis of the Treatment Approach to Immune Thrombocytopenia in the Real World.Cureus · 2019Article
- Initial management of immune thrombocytopaenia in adults based on risk stratification.Postgraduate medical journal · 2019Review
- Disrupted balance of CD4International journal of biological sciences · 2019Article
- Oral manifestations of thrombocytopaenia.The Saudi dental journal · 2018Review
- Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation.Oncotarget · 2017Review
- Seasonal variation of immune thrombocytopenic purpura related hospitalizations among adults in the USA: analysis of the nationwide inpatient sample database.Therapeutic advances in hematology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated accelerated platelet destruction and/or suppressed platelet production. Although the development of autoantibodies against platelet glycoproteins remains central in the pathophysiology of ITP, several abnormalities involving the cellular mechanisms of immune modulation have been identified, and the pathways behind the immune-mediated destruction of platelets have opened new avenues for the design of specific immunotherapies in an attempt to reduce the platelet destruction. This review is primarily focused on the recent literature with respect to immunopathological mechanisms in patients with ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.